Patients receiving bleomycin should be instructed to avoid which activity?

Patients receiving bleomycin should be instructed to avoid scuba diving primarily due to the risk of pulmonary toxicity, which is a potential adverse effect of the drug. Bleomycin is known to induce lung damage and can lead to interstitial pneumonitis or pulmonary fibrosis. Scuba diving involves significant changes in pressure and gas exchange, which can exacerbate any underlying pulmonary effects that might be present due to bleomycin treatment.

Underwater pressure may result in greater stress on a compromised respiratory system, increasing the risk of barotrauma or other lung-related complications. As a precautionary measure, it is essential for patients being treated with bleomycin to avoid this activity.

While there are considerations for activities like long-distance running or high-altitude flying due to the effects of chemotherapy and potential fatigue or altitude-related complications, the specific risk associated with scuba diving is more pronounced due to the direct impact of pressure changes on lung function. Swimming in chlorinated pools does not carry the same level of risk in relation to bleomycin's pulmonary effects.